ANI Pharmaceuticals Inc. (ANIP)

NasdaqGM: ANIP · Precio en tiempo real · USD

77.44

+0.57 (0.74%)

Al cierre: Aug 19, 2026, 8:00 PM

75.00

-3.87%

Fuera de horario: 7:32 PM

0.74% (1D)

No hay datos disponibles

Precio de compra	56.91
Capitalización de mercado	1.79B
Ingresos (TTM)	978.38M
Beneficio neto (TTM)	99.6M
Beta	0.46
EPS (TTM)	4.59
Ratio PER (TTM)	17
Adelante PE	7.41
P/B (TTM)	2.80
P/S (TTM)	1.83
Earnings Date	Nov 6, 2026

Precio de venta	103.53
Volumen	49,222
Volumen medio (20D)	339,311
Abierto	77.79
Anterior Cerrar	76.87
Rango del día	77.29 - 78.93
Rango de 52 semanas	70.15 - 99.50
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to nat...

[Leer más]

Industria Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Fecha May 5, 2000

Empleados 970

Bolsa de Valores NasdaqGM

Símbolo bursátil ANIP

Sitio web https://www.anipharmaceuticals.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de ANI Pharmaceuticals fueron 883.37M, un aumento de 43.78% en comparación con 614.38M del año anterior. Las ganancias fueron 78.34M, una disminución de -522.94%.

Estados financieros

Sorpresa de resultados

ANI Pharmaceuticals ha publicado sus resultados trimestrales en Aug 7, 2026:

Ingresos de $266.04M falla las estimaciones por $0, con 25.87% Crecimiento interanual.

EPS de 2.21 supera las estimaciones en 0.17, con 22.78% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que ANI Pharmaceuticals Inc. publique sus resultados el Nov 6, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

3 días hace · StockStory

The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q2 Earnings Call

ANI Pharmaceuticals’ second quarter was marked by strong year-on-year growth in its rare disease and generics businesses, but the market reacted negatively to the results. Management highlighted the r...

4 días hace · StockStory

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ANI Pharmaceuticals (NASDAQ:ANIP) and the b...